Forbes April 2, 2025
Inner Cosmos is a startup reinventing care for depressed patients unresponsive to conventional pharmaceutical therapies. Since the FDA granted the company a device exemption to initiate a feasibility study in 2022, it has fitted three patients with its Digital Pill device. This makes the company an early first mover in psychiatric brain-computer interfaces and ushers in a new era for the BCI field.
Writing new brain chemistry at the push of a button is not a new idea. Deep brain stimulation and other surgical implants have long been used in neuropsychiatric research as an investigational treatment in cases of severe mental illness, including treatment-resistant depression. For the trio who have joined this study seeking help, and others to follow from...
Today's Sponsors
Today's Sponsor